PNC Financial Services Group
DMAC icon

PNC Financial Services Group’s DiaMedica Therapeutics DMAC Stock Holding History

PNC Financial Services Group’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$129 Sell
19
-38
-67% -$301 ﹤0.01% 5081
2025
Q4 		$454 Sell
57
-393
-87% -$2.94K ﹤0.01% 4860
2025
Q3 		$3.09K Buy
+450
New +$2.44K ﹤0.01% 4379

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group's DMAC Position: Q1 2026 in Review

PNC Financial Services Group reduced its DiaMedica Therapeutics (DMAC) stake by 67% in Q1 2026, selling an estimated $301 and leaving 19 shares worth $129. The position accounts for ﹤0.01% of the portfolio, ranked #5081.

PNC Financial Services Group first reported a position in DMAC in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.09K in Q3 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • PNC Financial Services Group held 19 shares of DiaMedica Therapeutics worth $129 as of Q1 2026.
  • PNC Financial Services Group sold 38 DiaMedica Therapeutics shares in Q1 2026, an estimated $301.
  • DiaMedica Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #5081 holding.
  • PNC Financial Services Group first reported a position in DiaMedica Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • PNC Financial Services Group's DiaMedica Therapeutics position peaked at $3.09K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.